Published in Clin Interv Aging on January 01, 2008
Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol (2013) 0.98
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int (2011) 0.95
Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci (2010) 0.90
Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk? Clin Oral Investig (2012) 0.87
Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study. J Osteoporos (2011) 0.87
Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging (2012) 0.82
Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates. Oral Surg Oral Med Oral Pathol Oral Radiol (2015) 0.81
Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol (2014) 0.81
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.80
Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Prefer Adherence (2014) 0.80
The relationship of frequency of meat consumption and osteoporosis in Chinese postmenopausal women. Int J Clin Exp Med (2015) 0.80
Osteoporosis and bisphosphonate-related osteonecrosis of the jaw bone. ISRN Rheumatol (2011) 0.80
The effect of vitamin D and bisphosphonate on fracture healing: An experimental study. J Clin Orthop Trauma (2016) 0.78
Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study. BMC Musculoskelet Disord (2013) 0.77
Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study. Int J Med Sci (2013) 0.77
Bisphosphonates: do we know their role in adjuvant breast cancer treatment? Oncology (Williston Park) (2010) 0.75
Mandibular osteonecrosis due to bisphosphonate use. Turk J Urol (2015) 0.75
Cell Therapy Products in Menopausal Medicine. J Menopausal Med (2016) 0.75
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol (2017) 0.75
The role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res (2011) 0.75
Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study. J Bone Miner Res (2016) 0.75
Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries. Osteoporos Int (2016) 0.75
The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell (1992) 30.02
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Diagnosis of osteoporosis and assessment of fracture risk. Lancet (2002) 7.38
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Differences in mortality after fracture of hip: the east Anglian audit. BMJ (1995) 6.12
Osteoporosis. Lancet (2006) 5.40
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med (1999) 4.53
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Risk of mortality following clinical fractures. Osteoporos Int (2000) 3.76
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65
Epidemiology of osteoporotic fractures. Osteoporos Int (2004) 3.60
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 3.13
Osteoporosis: a still increasing prevalence. Bone (2006) 2.89
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc (2000) 2.80
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Race and sex differences in mortality following fracture of the hip. Am J Public Health (1992) 2.63
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin (2005) 2.57
Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int (2006) 2.53
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Prevention and management of osteoporosis. World Health Organ Tech Rep Ser (2003) 2.48
Survival experience of aged hip fracture patients. Am J Public Health (1989) 2.46
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int (1999) 2.28
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
The socioeconomic burden of fractures: today and in the 21st century. Am J Med (1997) 2.06
Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med (1996) 2.05
Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas (2004) 2.03
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med (1997) 2.00
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Patient-physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol (2004) 1.92
Renal failure with the use of zoledronic acid. N Engl J Med (2003) 1.89
Residual lifetime risk of fractures in women and men. J Bone Miner Res (2007) 1.82
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care (1997) 1.75
Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int (2003) 1.74
Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72
Preferences for medical collaboration: patient-physician congruence and patient outcomes. Patient Educ Couns (2005) 1.71
Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int (1998) 1.69
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int (2004) 1.60
The influence of patient preference on depression treatment in primary care. Ann Behav Med (2005) 1.55
Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int (1993) 1.53
Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int (2007) 1.51
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med (2000) 1.47
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract (2006) 1.46
The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab (2005) 1.43
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Aging. Osteoporos Int (1999) 1.39
Epidemiology of osteoporosis. Bone (1992) 1.38
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin (2005) 1.33
The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem (2006) 1.32
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin (2006) 1.32
Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res (2003) 1.31
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther (2002) 1.27
Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int (1995) 1.24
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
Mortality in women following hip fracture. J Chronic Dis (1983) 1.21
Epidemiology of osteoporosis. Osteoporos Int (1999) 1.20
Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J (2003) 1.17
The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin (2007) 1.17
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther (2006) 1.16
Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab (2006) 1.16
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab (2007) 1.11
Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int (2007) 1.10
Treatments for osteoporosis - looking beyond the HORIZON. N Engl J Med (2007) 1.10
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int (2003) 1.09
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
Consequences of poor compliance with bisphosphonates. Bone (2007) 1.09
Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf (2007) 1.08
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas (2004) 1.07
A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int (2002) 1.06
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine (2007) 1.03
A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc (2006) 1.00
The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord (2007) 0.99
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res (2001) 0.96
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom (2008) 2.21
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res (2004) 2.01
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol (2005) 1.84
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Muscle atrophy and bone loss after 90 days' bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study. Bone (2005) 1.65
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2003) 1.65
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res (2005) 1.39
Acute changes in neuromuscular excitability after exhaustive whole body vibration exercise as compared to exhaustion by squatting exercise. Clin Physiol Funct Imaging (2003) 1.39
Vascular adaptation to deconditioning and the effect of an exercise countermeasure: results of the Berlin Bed Rest study. J Appl Physiol (1985) (2005) 1.36
Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol (2005) 1.29
Is muscle power output a key factor in the age-related decline in physical performance? A comparison of muscle cross section, chair-rising test and jumping power. Clin Physiol Funct Imaging (2004) 1.28
Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin (2004) 1.28
Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int (2008) 1.26
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res (2004) 1.26
When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2004) 1.24
Treatment of chronic lower back pain with lumbar extension and whole-body vibration exercise: a randomized controlled trial. Spine (Phila Pa 1976) (2002) 1.23
Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab (2010) 1.21
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Impact of bed rest on conduit artery remodeling: effect of exercise countermeasures. Hypertension (2010) 1.17
Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol (2007) 1.17
Reproducibility of the jumping mechanography as a test of mechanical power output in physically competent adult and elderly subjects. J Am Geriatr Soc (2004) 1.11
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int (2010) 1.09
Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone (2013) 1.05
Long term bed rest with and without vibration exercise countermeasures: effects on human muscle protein dysregulation. Proteomics (2010) 1.02
Ryanodine receptor type-1 (RyR1) expression and protein S-nitrosylation pattern in human soleus myofibres following bed rest and exercise countermeasure. Histochem Cell Biol (2008) 1.00
WISE-2005: bed-rest induced changes in bone mineral density in women during 60 days simulated microgravity. Bone (2011) 1.00
Countermeasures against lumbar spine deconditioning in prolonged bed rest: resistive exercise with and without whole body vibration. J Appl Physiol (1985) (2010) 0.99
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin (2006) 0.99
Differential atrophy of the lower-limb musculature during prolonged bed-rest. Eur J Appl Physiol (2009) 0.99
Human skeletal muscle structure and function preserved by vibration muscle exercise following 55 days of bed rest. Eur J Appl Physiol (2006) 0.97
Prevention of bone loss during 56 days of strict bed rest by side-alternating resistive vibration exercise. Bone (2009) 0.96
Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone (2006) 0.95
Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women. J Bone Miner Res (2014) 0.93
Trabecular and cortical bone density and architecture in women after 60 days of bed rest using high-resolution pQCT: WISE 2005. J Bone Miner Res (2011) 0.93
No influence of age, gender, weight, height, and impact profile in achilles tendinopathy in masters track and field athletes. Am J Sports Med (2009) 0.92
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Muscle atrophy and changes in spinal morphology: is the lumbar spine vulnerable after prolonged bed-rest? Spine (Phila Pa 1976) (2011) 0.92
Heterogeneous atrophy occurs within individual lower limb muscles during 60 days of bed rest. J Appl Physiol (1985) (2012) 0.92
Changes in intervertebral disc morphology persist 5 mo after 21-day bed rest. J Appl Physiol (1985) (2011) 0.91
Magnetic resonance imaging assessment of trunk muscles during prolonged bed rest. Spine (Phila Pa 1976) (2007) 0.91
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab (2009) 0.91
Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol (2009) 0.90
The effects of rehabilitation on the muscles of the trunk following prolonged bed rest. Eur Spine J (2010) 0.89
Bed rest and cognition: effects on executive functioning and reaction time. Aviat Space Environ Med (2009) 0.88
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom (2008) 0.88
Age at first oral contraceptive use as a major determinant of vertebral bone mass in female endurance athletes. Bone (2004) 0.86
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. Bone (2011) 0.86
Bone mineral density and bone turnover in male masters athletes aged 40-64. Aging Male (2010) 0.86
Secondary osteoporosis: endocrine and metabolic causes of bone mass deterioration. J Osteoporos (2012) 0.84
Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med (2004) 0.84
Hypertrophy in the cervical muscles and thoracic discs in bed rest? J Appl Physiol (1985) (2013) 0.84
Incomplete recovery of lumbar intervertebral discs 2 years after 60-day bed rest. Spine (Phila Pa 1976) (2012) 0.84
Knee extensor fatigability after bedrest for 8 weeks with and without countermeasure. Muscle Nerve (2007) 0.83
Expression and regulation of Homer in human skeletal muscle during neuromuscular junction adaptation to disuse and exercise. FASEB J (2011) 0.83
Influence of vibration resistance training on knee extensor and plantar flexor size, strength, and contractile speed characteristics after 60 days of bed rest. J Appl Physiol (1985) (2009) 0.83
Tree-structured subgroup analysis of receiver operating characteristic curves for diagnostic tests. Acad Radiol (2012) 0.83
Decision making after 50 days of simulated weightlessness. Brain Res (2009) 0.83
Resistive simulated weightbearing exercise with whole body vibration reduces lumbar spine deconditioning in bed-rest. Spine (Phila Pa 1976) (2008) 0.82
The effect of bed rest and an exercise countermeasure on leg venous function. Eur J Appl Physiol (2008) 0.82
Localization and Segmentation of 3D Intervertebral Discs in MR Images by Data Driven Estimation. IEEE Trans Med Imaging (2015) 0.82
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int (2005) 0.82
Differential atrophy of the postero-lateral hip musculature during prolonged bedrest and the influence of exercise countermeasures. J Appl Physiol (1985) (2011) 0.82
Tonic-to-phasic shift of lumbo-pelvic muscle activity during 8 weeks of bed rest and 6-months follow up. J Appl Physiol (1985) (2007) 0.81
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol (2005) 0.81
Patellar tendinopathy in master track and field athletes: influence of impact profile, weight, height, age and gender. Knee Surg Sports Traumatol Arthrosc (2010) 0.81
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg (2008) 0.81
Resistive exercise versus resistive vibration exercise to counteract vascular adaptations to bed rest. J Appl Physiol (1985) (2009) 0.81
Superficial lumbopelvic muscle overactivity and decreased cocontraction after 8 weeks of bed rest. Spine (Phila Pa 1976) (2007) 0.80
Three-dimensional quantification of structures in trabecular bone using measures of complexity. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 0.80
Resistive exercises, with or without whole body vibration, prevent vertebral marrow fat accumulation during 60 days of head-down tilt bed rest in men. J Appl Physiol (1985) (2012) 0.79
Vertical jump performance after 90 days bed rest with and without flywheel resistive exercise, including a 180 days follow-up. Eur J Appl Physiol (2007) 0.79
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int (2003) 0.79
Comparative examination of human proximal tibiae in vitro by ultrasonic guided waves and pQCT. Ultrasound Med Biol (2011) 0.79
Anatomical sector analysis of load-bearing tibial bone structure during 90-day bed rest and 1-year recovery. Clin Physiol Funct Imaging (2011) 0.79
Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf (2008) 0.79
Muscle atrophy, pain, and damage in bed rest reduced by resistive (vibration) exercise. Med Sci Sports Exerc (2014) 0.78
Short-duration resistive exercise sustains neuromuscular function after bed rest. Med Sci Sports Exerc (2012) 0.78
Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab (2012) 0.78
Nitrosative stress in human skeletal muscle attenuated by exercise countermeasure after chronic disuse. Redox Biol (2013) 0.78
Modification of a device and its application for intralesional cryosurgery of old recalcitrant keloids. Arch Dermatol (2004) 0.78
Influence of prolonged bed-rest on spectral and temporal electromyographic motor control characteristics of the superficial lumbo-pelvic musculature. J Electromyogr Kinesiol (2010) 0.78
Effect of prolonged bed rest on the anterior hip muscles. Gait Posture (2009) 0.78
Resistive vibration exercise during bed-rest reduces motor control changes in the lumbo-pelvic musculature. J Electromyogr Kinesiol (2011) 0.77
Progressive adaptation in physical activity and neuromuscular performance during 520d confinement. PLoS One (2013) 0.77
Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc (2013) 0.77
Whole-body vibration versus proprioceptive training on postural control in post-menopausal osteopenic women. Gait Posture (2013) 0.77
Muscle X-ray attenuation is not decreased during experimental bed rest. Muscle Nerve (2013) 0.77
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol (2014) 0.76
Bisphosphonates and atypical femoral fractures. N Engl J Med (2010) 0.76